Novogene Technology, a Beijing-headquartered genomic services provider, has raised a $75 million Series B round from Chinese investors including CMB International, SDIC Innovation Investment and Shanghai Sigma Square Capital.
Indian technology investor Kalaari Capital has invested $6 million across domestic start-ups, AffordPlan and Active Intelligence.
A fund controlled by China’s State Development & Investment Corporation (SDIC) has led a $260 million Series D round of funding for Innovent Biologics, a domestic biopharmaceutical company working on treatments for cancer, autoimmune disorders and heart...
Australia’s Impact Investment Group has raised A$13 million ($10 million) for a domestically focused venture capital fund. The initial target was A$10 million.
ORI Healthcare Fund, a Chinese sector-focused fund launched by former investment banker at Goldman Sachs, has led a $100 million Series C round for Kymab Group, a UK bio-pharmaceutical company focused on antibody drug discovery.
Having lost out to KKR when bidding for Panasonic Healthcare two years ago, Mitsui & Co. seized upon a second chance to get involved and offer the company access to its global network of medical assets
KKR has sold a 22% stake in Panasonic Healthcare, a Japanese medical equipment manufacturer in which it acquired a majority interest in 2014, to Mitsui & Co. for JPY54.1 billion ($510 million).
CDH Investments and CCB International have sold their stakes in Harmonicare Medical Holdings, operator of 11 women and children’s hospitals in China, to Taikang Insurance Group for HK$815.2 million ($105.1 million).
Hony Capital has reiterated its commitment to helping Chinese companies go global, in addition to supporting international firms that want to maximize their exposure to China – and the firm established a presence in Shenzhen to address these opportunities.
Ascendent Capital Partners has committed RMB50 million ($7.36 million) to BioChain Beijing, a Chinese biotech company that focuses on early detection of cancer.
Betta Pharmaceuticals, a Chinese VC-backed drug developer backed by several venture investors, has completed a RMB720 million ($106 million) IPO on Shenzhen’s Growth Enterprise Market Board.
J-Star will take control of Japanese insurance provider Hunel FEA through a bolt-on acquisition by existing portfolio company Nihon Hoken Service.
Eight Roads Ventures India sees considerable strengths in Eywa to tackle the lucrative US generic pharmaceuticals market
The Everstone Group has bought a majority stake in Indian pharmaceutical developer Rubicon Research for INR2.2 billion ($32.9 million), providing an exit for Kotak Private Equity.
Asia Pacific Medical Group (APMG), a medical platform owned by Bain Capital, has agreed to sell Singapore and Malaysia-based plastic surgery brand The Sloane Clinic to China Medical (International) Group (CMIG).
Singapore's Temasek Holdings has committed $250 million to hospital operator Columbia Pacific Management for a joint venture in China.
Trustbridge Partners has led a $30 million Series B round for US-based genetic testing company Veritas Genetics.
Chinese boutique investment bank and advisory firm CEC Capital Group – formerly known as China eCapital – has agreed to buy US-based counterpart Siemer & Associates (S&A).
Eight Roads Ventures India and US-based F-Prime Capital - both of which are controlled by Fidelity - have joined a $30 million investment in Singapore and India-based drug manufacturer Eywa Pharma.
Dubai-based private equity investor Evolvence Capital has committed $6.2 million to Indian in-vitro fertilization (IVF) clinic chain Oasis Centre for Reproductive Medicine.
Singapore-listed energy trading company New Silkroutes Group (NSG) has formed a joint venture with three parties to develop private equity funds targeting healthcare and infrastructure in emerging and developed Asia.
The International Finance Corporation (IFC) has invested $11 million in Indonesia-based Aneka Gas Industri as part of the gas production company’s domestic IPO.
J-Star will take control of Japanese aged care provider Live Cross through a bolt-on acquisition by the firm’s existing portfolio company Kairos Tokyo.
Innovation Network Corporation of Japan (INCJ) has committed up to JPY10.4 billion ($102.6 million) to funds managed by domestic VC firms MedVenture Partners and Universal Materials Incubator.